ST-00937 / SEED Therapeutics - LARVOL DELTA

SEED Therapeutics Highlights Breakthrough Advances in Targeted Protein Degradation at AACR 2025 (GlobeNewswire) - "At AACR, SEED reported the following findings: ST-00937 degrades RBM39 to undetectable levels in A673 Ewing sarcoma cells, both in vitro and in vivo; Treatment with ST-00937 leads to complete elimination of established A673 tumors within two weeks; Mechanistic studies demonstrate that ST-00937 impairs homologous recombination repair pathways in A673 cells... SEED expects to file an Investigational New Drug (IND) application for its next-generation RBM39 degrader, derived from ST-00937, in mid-2025...The second presentation at AACR highlighted a novel bifunctional degrader strategy that combines two PROTACs using two E3s targeting KRAS G12D...Key findings presented include: VHL-based PROTACs targeting KRAS G12D display the classic hook effect at high concentrations; KEAP1-based PROTACs synergize with VHL-based PROTACs to enhance KRAS G12D degradation and promote apoptosis in pancreatic cancer models....Synergistic effects were also observed..."

IND • Preclinical • Ewing Sarcoma • Pancreatic Cancer • Sarcoma

SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago (GlobeNewswire) - "Two PROTAC synergy using two E3 ligases for achieving levels of degradation of KRAS G12D not achieved with single PROTACs, will be presented by the lab of Luca Busino, PhD, from the University of Pennsylvania, on April 27th....SEED’s first IND candidate project targeting RBM39: Ewing sarcoma will be presented as an important target on April 30th."

Preclinical • Ewing Sarcoma

Targeting Ewing sarcoma with a novel RBM39 degrader: DNA damage repair pathway effects (AACR 2025) - "The RBM39 molecular glue degrader ST-00937 therefore demonstrates total tumor regression in a model of Ewing sarcoma. Mechanistic studies indicate that the robust activity of ST-00937 involves deficient homologous recombination repair. Continued research in our lab will add further insights into the mechanism of action of RBM39 degraders in this cancer of high unmet need."

Breast Cancer • Ewing Sarcoma • Oncology • Sarcoma • Solid Tumor • BRCA1 • CASP3 • EWSR1 • FLI1 • HRD • RAD51D • RBM3 • RBM39

BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics (GlobeNewswire) - "The SEED TPD platform referred to as RITE3, has translated the scientific breakthrough...Differentiated from other molecular glue companies, which are mainly 'E3 centric', SEED’s RITE3 platform is 'target centric' and uses novel E3 ligases for protein targets. With detectable weak basal interaction between selected E3 and protein target, the binder hit rates from its high throughput screening is higher...SEED expects to file an IND in early 2025 for its IND Candidate oral RBM39 degrader, for the treatment of rationally selected cancer indications; SEED R&D has a focus on the development of orally delivered molecular glues for CNS indications, with a lead internal program against Tau...Eli Lilly is a current investor and R&D collaborator with upfront and milestone payments up to $780 million....'I'm delighted to announce SEED's substantial progress...Tau degraders for neurodegeneration advancing towards lead molecule status towards the end of 2024.'"

IND • Licensing / partnership • New molecule • CNS Disorders • Oncology • Solid Tumor

SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at 'Targeted Protein Degradation Think Tank' Symposium (GlobeNewswire) - "SEED Therapeutics Inc...announced at its Monday, October 23, 2023 Targeted Protein Degradation (TPD) Think Tank symposium that it had successfully discovered a ST-00937, a new chemical entity (NCE) molecular glue that has already achieved IND Candidate status and will be advanced for the treatment of cancers in SEED’s first IND filing, as early as 2024."

IND • Oncology

SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium (GlobeNewswire) - "SEED Therapeutics...announced at its Monday, October 23, 2023 Targeted Protein Degradation (TPD) Think Tank symposium that it had successfully discovered a ST-00937, a new chemical entity (NCE) molecular glue that has already achieved IND Candidate status and will be advanced for the treatment of cancers in SEED’s first IND filing, as early as 2024."

IND • New molecule • Oncology